New clinical trial data reveals that while Covid-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substantially within 3 months.
Looking at data from more than 100 different animals, researchers have revealed some insights into aging that may help better understand longevity in humans.
An NIH study describes the immune response triggered by Covid-19 infection that damages the brain’s blood vessels and may lead to short- and long-term neurological symptoms.
NEI researchers have identified a new genetic disease that affects the macula, a small part of the light-sensing retina needed for sharp, central vision. The findings on this novel, yet-to-be-named macular dystrophy were reported in JAMA Ophthalmology.
NIH has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods.
Treating adults hospitalized with Covid-19 with infliximab or abatacept—drugs widely used to treat certain autoimmune diseases—did not shorten recovery time but did substantially improve clinical status and reduced deaths, according to an ACTIV trial.
Americans ages 64 and younger with commercial health insurance who live with sickle cell disease (SCD) pay almost quadruple the out-of-pocket medical costs over their lifetimes.
Some studies suggest that consuming high levels of antioxidants—compounds commonly found in vegetables and fruits that help protect cells from molecular damage—may help prevent the development of dementia.